Market Cap 2.05B
Revenue (ttm) 167.13M
Net Income (ttm) -4.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 37.26
Profit Margin -2.41%
Debt to Equity Ratio 0.00
Volume 171,300
Avg Vol 125,488
Day's Range N/A - N/A
Shares Out 19.26M
Stochastic %K 60%
Beta 1.07
Analysts Strong Sell
Price Target $144.22

Latest News on LGND

Ligand to Participate in March Investor Conferences

Mar 3, 2025, 7:00 AM EST - 7 weeks ago

Ligand to Participate in March Investor Conferences


Looking Back On Ligand Pharmaceuticals

Feb 3, 2025, 2:59 PM EST - 2 months ago

Looking Back On Ligand Pharmaceuticals


Ligand to Present at Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 5 months ago

Ligand to Present at Stifel 2024 Healthcare Conference


Ligand Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:01 PM EDT - 9 months ago

Ligand Reports Second Quarter 2024 Financial Results


Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29, 2024, 2:43 PM EDT - 9 months ago

Ligand Pharmaceuticals: Solid Performer Performing Solidly


Ligand to Acquire APEIRON Biologics AG for $100 Million

Jul 8, 2024, 7:00 AM EDT - 10 months ago

Ligand to Acquire APEIRON Biologics AG for $100 Million


Ligand to Participate in Upcoming Investor Conferences

May 23, 2024, 4:59 PM EDT - 11 months ago

Ligand to Participate in Upcoming Investor Conferences


Ligand Reports First Quarter 2024 Financial Results

May 7, 2024, 4:00 PM EDT - 1 year ago

Ligand Reports First Quarter 2024 Financial Results


Ligand Pharma's at-home skin treatment gets FDA approval

Jan 5, 2024, 5:21 PM EST - 1 year ago

Ligand Pharma's at-home skin treatment gets FDA approval


Ligand Pharmaceuticals: A Complicated Tale

Nov 15, 2023, 1:22 PM EST - 1 year ago

Ligand Pharmaceuticals: A Complicated Tale